Table 4 NSABP FB-7: association of FCGR3A-158F/V single nucleotide polymorphisms (SNP) with pathologic complete response (pCR)
Treatment arm | pCR status | F/F patients | pCR rate in F/F (%) | V/V or V/F patients | pCR rate in V/V or V/F (%) | Compare F/F to V/F and V/F P values |
|---|---|---|---|---|---|---|
Trastuzumab | No pCR | 7 | 13 | 3 | 72.7 | 0.02 |
pCR | 1 | 8 | ||||
Neratinib | No pCR | 9 | 25 | 6 | 50.0 | 0.4 |
pCR | 3 | 6 | ||||
Trastuzumab plus neratinib | No pCR | 4 | 43 | 3 | 62.5 | 0.6 |
pCR | 3 | 5 | ||||
All arms | No pCR | 20 | 25.9 | 12 | 61.3 | 0.009 |
pCR | 7 | 19 |